Pharmaceutical Group Limited by Share Ltd
The leader in the field of health China liver
Pharmaceutical Group is an innovative pharmaceutical group company integrating scientific research, production and sales, is the largest liver health drug R & D and production base, as a key national high-tech enterprises, the State Torch Program new medicine industry base of key enterprises, in 2015 ranked the top 100 enterprises ranked seventeenth, ranked second in the pharmaceutical industry. In 2015, in the domestic hospital liver disease drug market share of 21.9% consecutive years, ranking the industry first.
Always will be scientific and technological innovation as an important strategy for enterprise development, is the domestic research into one of the most innovative drug pharmaceutical companies. The Pharmaceutical Research Institute for innovation, "the new liver medicine engineering technology research center", "national post doctoral research station, national enterprise technology center and other high-level R & D in the platform have been established, continuously enhance the capability of independent innovation. With the development of enterprises and enhance research and development capabilities, R & D investment will also look to multinational corporations, gradually increase the revenue from sales of 8% to 15%. Currently, the Institute in the research project more than and 180, of which a new class of drugs, bio medicine, 21, a total of 36.
Has three production bases, with a total area of more than 800 acres, covering an area of 160 acres of incubation base, covering an area of more than and 200 acres of raw materials base, covering an area of 480 acres of preparation base. Preparation base in accordance with the European Union and the United States FDA standard design and construction, small volume injections obtained the country's first GMP certificate, oral solid preparations obtained the first GMP certificate. In June 2014, the preparation base through the EU certification, access to the German Drug Administration issued by the EU recognized GMP certification. The acquisition of these certificates marks the pharmaceutical production quality and management level in the forefront of the national pharmaceutical industry. At present, in preparation for the four leading products into the international market, the future of these drugs will become a new tool to open the international market.
Products in the field of treatment involving liver disease, tumor, respiratory, digestive, infection and other diseases, 10 annual sales of billions of dollars of products formed a "billion products group", the annual sales of 2 billion yuan 2 products, respectively for a class of drugs and the first domestic listed Magnesium Isoglycyrrhizinate Injection Entecavir Dispersible Tablets. In addition to the strong field of liver disease, the anti-tumor field also formed a unique product line, blood tumor products of decitabine and imatinib, dasatinib domestic first imitation; products of solid tumor capecitabine approved a new drug imatinib, Ernesto entered the three phase of clinical tumor, is expected to become the field of heavy product. Breathing, antibiotics, endocrine and other fields, will also be the focus of future development of enterprises.
Future development, the pharmaceutical industry will continue to strengthen the core competitiveness, establish a sound scientific and efficient R & D system, so that the company's R & D level has always been in line with the international frontier. The enterprise development for scientific research strength among the nation's top five pharmaceutical enterprises, the comprehensive strength of the national top ten large pharmaceutical group; and start the internationalization strategy, the enterprise to build a science and technology, as the core of the international pharmaceutical company.
